GBPM: GRID-based pharmacophore model: concept and application studies to protein-protein recognition

MOTIVATION Automatic procedures to obtain pharmacophore models from experimentally determined macromolecular complexes can help in the drug discovery process, especially when protein-protein recognition plays an important biological role. RESULTS The GRID-based pharmacophore model (GBPM) is a fully objective method for defining most relevant interaction areas in complexes deriving pharmacophore models from three-dimensional (3D) molecular structure information. It is based on logical and clustering operations with 3D maps computed by the GRID program on structurally known molecular complexes. In this manuscript we describe the concept and discuss application examples regarding protein-protein recognition. In particular two complexes selected in the Protein Data Bank have been tested to evaluate the GBPM capability to identify interaction areas. The results obtained show the capabilities of this new bioinformatic method.

[1]  S. Pickett,et al.  GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. , 2000, Journal of medicinal chemistry.

[2]  G. Cruciani,et al.  Hydrogen bonding interactions of covalently bonded fluorine atoms: from crystallographic data to a new angular function in the GRID force field. , 2004, Journal of medicinal chemistry.

[3]  Thierry Langer,et al.  Chemical feature-based pharmacophores and virtual library screening for discovery of new leads. , 2003, Current opinion in drug discovery & development.

[4]  J. Alvarez.  High-throughput docking as a source of novel drug leads. , 2004, Current opinion in chemical biology.

[5]  B Testa,et al.  Predicting blood-brain barrier permeation from three-dimensional molecular structure. , 2000, Journal of medicinal chemistry.

[6]  M. Pastor,et al.  A strategy for the incorporation of water molecules present in a ligand binding site into a three-dimensional quantitative structure--activity relationship analysis. , 1997, Journal of medicinal chemistry.

[7]  Christopher Chin,et al.  Dimer Dissociation Is Essential for Interleukin-8 (IL-8) Binding to CXCR1 Receptor* , 2004, Journal of Biological Chemistry.

[8]  Stephen F. Betz,et al.  Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain , 2000, Nature.

[9]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[10]  Mika A. Kastenholz,et al.  GRID/CPCA: a new computational tool to design selective ligands. , 2000, Journal of medicinal chemistry.

[11]  A. Gronenborn,et al.  Three-dimensional structure of interleukin 8 in solution. , 1991, Biochemistry.

[12]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[13]  Saul H Rosenberg,et al.  Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. , 2004, Journal of medicinal chemistry.

[14]  G. Salvesen,et al.  The BIR domain of IAP-like protein 2 is conformationally unstable: implications for caspase inhibition. , 2005, The Biochemical journal.

[15]  K. Das,et al.  Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. , 2005, The Biochemical journal.

[16]  Young Chul Park,et al.  Structural Basis of Caspase Inhibition by XIAP Differential Roles of the Linker versus the BIR Domain , 2001, Cell.